Overview

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health Organization (WHO) functional class in humans with pulmonary artery hypertension (PAH).
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
Mayo Clinic
The Cleveland Clinic
Treatments:
Metformin